Chief Executive Officer
Per Andersson joined XSpray in September 2006. He has more than 9 years of successful executive management experience in research, development and commercial operations. Most recently, Dr. Andersson served as Science Director of Gyros being one of the main inventors of the Gyros technology. Dr. Andersson has published more than 25 scientific publications and book chapters and is the inventor of more than 30 patent families (Assignee: University of Alberta and Gyros AB) Prior to Gyros Dr Andersson held a position as senior scientist at Amersham Pharamcia Biotech. He has commercial experience including business development and management of long term international partnerships. Dr. Andersson gained a Ph.D. in Analytical Chemistry from Stockholm University, Sweden in 1995 and have worked as a post-doc in Australia and Canada.
Science Director, Co-Founder
Co-founded XSpray in November 2003 and has acted as Chief Scientific Officer and has more than 15 years of broad experience in the international pharmaceutical industry, including 10 years as a senior consultant for Astra Zeneca where he was responsible for the early development of industrial pharmaceutical particle formation using Supercritical Fluids. Dr. Demirbüker has over 20 publications and is the inventor of several patent families related to Supercritical Fluid technology. Dr Demirbüker received his Ph.D. in Analytical Chemistry from Stockholm University, Sweden in 1992.
Vice President Operations
Gérald Jesson joined XSpray in September 2007. His accomplishments include founding two companies in Sweden, one of which, Capture Device AB was sold to Biomotif AB in 2007. He worked for Gyros for 7 years as a Scientist, and has rigths to more than 15 patents. He has also worked at the Karolinska Institute in Stockholm and VIRBAC S.A. in Nice, France.
Andreas Konar joined XSpray in 2010. He has more than 30 years of broad-based experience in business development, R & D licensing, clinical research and formulation development in the pharmaceutical industry. He has held positions as Vice President at LifeCycle Pharma A/S, A.L. Pharma Inc. and Dumex Ltd., in Copenhagen, Denmark, as well as Recordati SpA in Milan, Italy. Prior to this, he held Section Head, Clinical Scientist and Project Leader positions at AstraZeneca in Sweden, as well as various academic positions in Physical and Organic Chemistry. Dr. Konar serves on the Board of Directors of Ground Zero Pharmaceuticals, Inc. in Irvine, CA, USA.